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Summary
Objective and methods
Finding effective solutions to curb the obesity epidemic is a great global public health
challenge. The need for long-term follow-up necessitates weight loss trials conducted
in real-world settings, outside the confines of tightly controlled laboratory or clinic con-
ditions. Given the complexity of eating behaviour and the food supply, this makes the
process of designing a practical dietary intervention that stands up to scientific rigor dif-
ficult. Detailed information about the dietary intervention itself, as well as the process of
developing the final intervention and its underlying rationale, is rarely reported in scientific
weight management publications but is valuable and essential for translating research
into practice. Thus, this paper describes the design process and underlying rationale
behind the dietary interventions in an exemplar weight loss trial – the TEMPO Diet Trial
(Type of Energy Manipulation for Promoting optimal metabolic health and body compo-
sition in Obesity). This trial assesses the long-term effects of fast versus slow weight loss
on adiposity, fat free mass, muscle strength and bone density in women with obesity
(body mass index 30–40 kgm!2) that are 45–65 years of age, postmenopausal and
sedentary.
Results and conclusions
This paper is intended as a resource for researchers and/or clinicians to illustrate how
theoretical values based on a hypothesis can be translated into a dietary weight loss
intervention to be used in free-living women of varying sizes.
Keywords: Clinical protocol, dietary protein, diet-reducing, energy intake
Introduction
Seeking effective solutions to treat the obesity epidemic is
one of the greatest health challenges facing countries all
over theworld. Increasingly, obesity is regarded as a disease
in its own right (1–3) and is also a risk factor for a large
number of non-communicable, metabolic and mechani-
cal disorders, the risk of which increases on a continuum
with increasing adiposity (4). Lifestyle modification –
dietary interventions, alterations in physical activity and
behavioural changes – remains the cornerstone of
obesity management especially in the community (5).
Consequently, dietary weight loss trials are an important
area of research for informing evidence-based obesity
treatments in clinical practice.
The process of translating evidence from research into
clinical practice can take many years (6). An important
distinction to make when looking at evidence to inform
clinical practice is whether a study is an efficacy or an
effectiveness study. Although difficult to completely dif-
ferentiate between the two, efficacy studies are usually
conducted within the confines of tightly controlled labo-
ratory conditions and in a narrowly defined population,
with a focus on maximizing internal validity by minimizing
confounding variables (7). Effectiveness studies, on the
other hand, are conducted in ‘real-world’ settings and
with a broader population, with a focus on maximizing
external validity or generalizability to the population at
large (7). Effectiveness studies are important for weight
management interventions to allow greater generalization
of the findings to a primary care setting. An important
example of this is the POWER trials (Practice-based Op-
portunities for Weight Reduction), a collaboration of three
separate primary care interventions with a common focus
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on weight management and outcome measures (8–11).
These studies have provided evidence that effective
weight management interventions can be delivered in a
primary care setting. In order to bridge the gap in trans-
lation of research into clinical practice, the design of
research at all stages (including efficacy studies) should
consider the clinical utility of the dietary intervention that
is being tested and report greater detail of intervention
characteristics (6,12). If efficacy studies are designed
from a practice perspective, this would allow greater
translation into effectiveness studies and ultimately into
clinical practice (12,13).
The need for long-term follow-up in weight loss trials
necessitates that even efficacy trials are conducted in
free-living conditions, outside the confines of tightly
controlled laboratory conditions. However, given the
complexity of eating behaviour and the food supply,
designing a dietary intervention that can be adapted to
free-living conditions, which also stands up to scientific
rigor, is difficult. However, such detailed information
about the process of designing dietary interventions and
their underlying rationale is rarely reported in articles
about clinical weight loss trials. Therefore, the aim of this
paper describes the design process and underlying ratio-
nale behind the dietary interventions of an exemplar
weight loss trial (details in the succeeding texts). The in-
tention is for this paper to be a resource for researchers
and/or clinicians by illustrating how theoretical values
based on a hypothesis can be translated into a dietary
weight loss intervention to be tested in free-living women
of varying sizes.
The TEMPO Diet Trial (Type of Energy
Manipulation for Promoting optimal
metabolic health and body composition
in Obesity)
The TEMPO Diet Trial is designed to assess the long-
term effects of fast versus slow weight loss on adipos-
ity, fat free mass, muscle strength and bone density in
women who are 45–65 years of age, postmenopausal,
sedentary (defined here as less than 3 h of structured
physical activity per week) and with obesity (body mass
index [BMI] 30–40 kgm!2). The trial is registered with the
Australia and New Zealand Clinical Trials Registry
(ACTRN12612000651886). It is a 3-year trial consisting
of a 1-year intervention (weight loss) phase, with follow-
up at 2 and 3 years.
The TEMPO Diet Trial is not strictly an efficacy study or
an effectiveness study; however, it is conducted in a re-
search setting and in a narrowly defined population and
has been designed to maximize clinical utility by drawing
on existing resources and clinical practice guidelines (as
described in the succeeding texts).
Modelling of potentially eligible
participants
Nutritional requirements differ for persons of different
age, sex, height, weight and physical activity level.
Hence, the first consideration in designing the dietary in-
terventions for the TEMPO Diet Trial was to model (or pre-
dict) characteristics of the potentially eligible population
so that accurate dietary prescriptions and the logistics
of implementation could be determined prior to seeing
participants. A detailed overview of how this was con-
ducted is provided in the Supporting information. In brief,
we used the average height of women in Australia in our
age group (45–65 years) and in our BMI inclusion criteria
(30–40 kgm!2) to determine that the weight of potentially
eligible women would likely fall between 68 and 115 kg.
We then calculated the estimated energy expenditure
(EEE) for all potentially eligible women within these weight
ranges using the Harris–Benedict equation (14).
Developing the foundations for the
dietary weight loss interventions
Energy restriction
As the TEMPO Diet Trial compares fast versus slow
weight loss, we aimed to achieve a large difference in
energy restriction between the two intervention arms.
We thus established energy restriction targets as this
would take into account differences between participants
in baseline requirements, important for achieving our goal
of comparing fast versus slow weight loss. This strategy
is in contrast to other common approaches in clinical
weight loss trials, which focus on a specific energy intake
target (e.g. 5000–6300 kJ [1200–1500 kcal] per day) (15).
However, if we used an energy intake target, this could re-
sult in wide variability in the rate of weight loss within each
arm and less differences between arms, because the rate
of weight loss is dependent not only on energy intake but
also on energy requirements, which can vary widely in a
potential participant population (refer to Supporting infor-
mation, Figure S2, for examples).
We aimed to achieve severe energy restriction and
moderate energy restriction in the fast and slow weight
loss groups, respectively. We defined severe energy re-
striction as a minimum of 65% restriction relative to EEE
(target range 65–75%) and moderate energy restriction
as a maximum of 35% restriction relative to EEE (target
range 25–35%). As such, we were aiming for a minimum
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difference in energy restriction between women in the fast
versus slow weight loss arms of 30% of EEE.
Protein intake
An additional requirement in designing the dietary inter-
ventions for the TEMPO Diet Trial was to match protein
intake between the groups as closely as possible. This
is because protein intake has been shown to have a
dose–response effect on the composition of weight that
is lost during an energy-restricted diet, as well as appetite
(16–18) – both of which are outcomes of the TEMPO Diet
Trial. Further, protein intake needed to be matched on an
absolute (gram per kilogram of body weight per day) as
opposed to a relative basis (% of energy from protein).
This is because of the large differences in prescribed en-
ergy restriction (and therefore prescribed energy intake)
among potential participants, which, if protein intake were
based on a percentage of energy, would result in large
absolute differences in protein intake between the fast
and slow weight loss groups.
In choosing the absolute protein target to use for the
trial, consideration was given not only to the recom-
mended dietary intake (RDI) of protein and the available
evidence on protein intakes shown to minimize loss of
fat free mass and to attenuate the drive to eat during
weight loss but also to what would be feasible within both
the fast and slow weight loss arms. The RDI of protein in
Australia for women aged 51–70 years is 0.75 g per kg of
actual body weight per day (19). In order to prevent or at-
tenuate loss of fat free mass during energy restriction and
weight loss in people with overweight or obesity, a protein
intake of between 0.8 and 1.2 g per kg of actual body
weight per day is suggested (16–18,20). The upper level
of 1.2 g per kg per day appears to be the most beneficial
in terms of body composition (20); however, this was
deemed too high for the purposes of this study, as it
would not be feasible to achieve this level of protein in-
take within the fast weight loss arm, given the severe en-
ergy restriction involved. Similarly, the minimum of 0.8 g
per kg per day was deemed too low for this trial because
it is likely that participants in the slow weight loss arm
would inadvertently consume more than 0.8 g of protein
per kg of body weight per day because of the difficulty
of maintaining such a low protein intake with only moder-
ate energy restriction. For instance, the latest Australian
National Nutrition Survey found that women aged
51–70 years consumed, on average, 18.9% of energy
from protein (21). A potential participant in the trial of av-
erage height (1.62m) and with a BMI of 35 kgm!2 would
weigh 91 kg and have an EEE of 9900 kJ (Supporting
information, Figure S2). Because 1g of protein provides
17 kJ, 18.9% of energy as protein in weight maintenance
would equate to 110g per day or 1.2 g per kg body weight.
Therefore, a target protein intake of 1 g per kg was chosen
as it represented a suitable compromise between ade-
quate (0.8 g per kg) and optimal (1.2 g per kg) protein
intake that was also feasible for both intervention arms.
How the two dietary weight loss inter-
ventions were developed
Development of the fast weight loss intervention
We chose to achieve fast weight loss via severe energy re-
striction using commercial formulated meal replacement
very low energy diet (VLED) products (as opposed to
food). This is because these products would not compro-
mise micronutrient intake and are routinely used in clinical
practice. Given our target protein intake of 1 g per kg of
actual body weight per day and given the varying body
weights of potential participants in the trial, a number of
different fast weight loss regimens were needed for the
trial. As well as aiming to achieve this target for protein
intake, we also needed to ensure that the diet involved
severe energy restriction (65–75% of EEE) and that carbo-
hydrate intake was low enough to induce ketosis. Ketosis
is a metabolic state involving an elevation in circulating
concentrations of ketone bodies and is thought to be a
key factor in helping to prevent a compensatory increase
in the drive to eat with severely restricted energy intake
(22). Whilst the exact level of carbohydrate intake at which
ketosis occurs is not known, ketosis is thought to be
unlikely when carbohydrate intake is above 100g per
day (23,24). Thus, in addition to the previously mentioned
targets for energy restriction and protein intake, we also
wanted to ensure a carbohydrate intake of less than
100g per day.
When we examined the VLED products currently avail-
able in Australia, it became apparent that it was not going
to be feasible to achieve a protein intake of 1 g per kg
using the products alone without pushing energy and
carbohydrate intake above target levels for our trial. For
example, a woman with a BMI of 35 kgm!2 and of aver-
age height for women in Australia of our age group
(1.62m) (25) would weigh 91 kg and require six Optifast®
shakes per day (17.5 g protein per sachet, Table 1),
resulting in a daily energy intake of 5200 kJ (870 kJ per
sachet, Table 1) – which is only 47% energy restriction
given her EEE of 9900 kJ per day (Supporting information,
Figure S2) – and a daily carbohydrate intake of well
over 100 g (135 g, 22.5 g per sachet, Table 1). Therefore,
protein supplementation would be required in our
fast weight loss intervention. This could potentially be
achieved by including a small portion of lean protein in
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the diet (e.g. beef, chicken or fish). However, the practice
of supplementing VLED products with lean protein may
decrease compliance (26,27), as paradoxically, restricting
choice to solely the VLED products is what is thought to
promote adherence (28). Thus, we used a carbohydrate-
free protein supplement product that could be added
to the VLED products. To this end, we selected a whey
protein isolate product (Beneprotein®, Nestlé HealthCare
Nutrition, Inc., Florham Park, NJ, USA), which readily
dissolves in water because it is intended for use in tube
feeds, contains no carbohydrate and is unflavoured. This
was in contrast to many of the protein supplement prod-
ucts that are readily available in Australian pharmacies,
which can contain significant quantities of carbohydrate
and are usually flavoured.
To determine the most suitable VLED product to use in
our trial, we modelled the average nutritional composition
of two commercially available products that are readily
available, contain sound micronutrient composition
and are routinely (29) used as VLEDs (Optifast®, Nestlé
Healthcare Nutrition, Rhodes, NSW, Australia; and
KicStart™, Prima Health Solutions Pty Ltd., Frenchs
Forest, NSW, Australia, Table 1). Nutritional composition
and cost in Australian Dollars were taken from the respec-
tive manufacturers’ websites (30,31). We chose to only
consider the shake varieties of the VLED products and
did not include soup, dessert or bar varieties, because
in our clinical experience, shakes are the most popular.
The average energy and macronutrient content of the
Optifast® and KicStart™ shakes and Beneprotein®, as
well as price, are shown in Table 1.
To design the different fast weight loss regimens, we
generated a series of regimens for each of the VLED prod-
ucts based on varying the number of shakes and scoops
of Beneprotein®. We worked backwards from our three
main desired features of the diet: a daily protein intake of
68–115g per day (corresponding to the potential weights
of our eligible participants of 68–115 kg), a severe energy
restriction of 65–75% of EEE, and a daily carbohydrate
intake of less than 100g. We started with a regimen con-
taining a minimum of three shakes (as three are required
to meet micronutrient requirements), and thereafter, each
regimen increased by one scoop of Beneprotein® per
day (Table 2). We increased Beneprotein® up to a maxi-
mum of two scoops per shake (i.e. six per day for a regi-
men based on three shakes) before devising a regimen
with an increased number of shakes per day. The maxi-
mum of two scoops of Beneprotein® per shake was
based on taste testing in which we found that two scoops
could be added during the preparation of a shake before it
started to affect the taste. Note that there were no regi-
mens with Optifast® involving less than two scoops
of Beneprotein®, as these were required to meet the
minimum protein intake of 68 g with Optifast® shakes
(Table 2). Once we had regimens that represented all the
required protein intake targets of 68–115g per day,
unnecessary regimens were deleted. For example, if a
regimen with four shakes resulted in a protein intake that
was also met by a regimen with three shakes, we only
included the regimen with three shakes, in order to
minimize energy and carbohydrate intake, as well as cost.
Indeed, the first regimen in Table 2 to include four
Optifast® shakes has four scoops of Beneprotein® rather
than 0, 1, 2 or 3, as the protein intake of these regimens
could be met with regimens including three Optifast®
shakes.
To compare the regimens based on the two VLED
products shown in Table 2, we plotted the daily energy
intake, daily carbohydrate intake and cost for a program
of our intervention duration (16weeks) against the protein
intake provided by each regimen (Figures 1–3). This
demonstrated that whilst the two VLED products were
comparable in energy content when compared on a per
shake basis (Table 1), because the KicStart™ shakes
contained an average of 4.8 g more protein, 4.1 g less
carbohydrate and retailed at AUD0.55 less than Optifast®
shakes (AUD1.17 less if KicStart™ is purchased in bulk), it
was better suited to our intervention aims of meeting
protein requirements whilst keeping energy, carbohydrate
intake and cost within stringent upper limits. For example,
if we compare the energy, carbohydrate and cost saving
for three women of average height (1.62m) with a
BMI of 30, 35 and 40 kgm!2 respectively, using KicStart™
instead of Optifast® results in a daily saving per person of
Table 1 Nutritional composition and cost of the very low energy diet and protein supplement products used to model potential fast weight loss
regimes
Product Energy (kJ) Protein (g) Fat (g) Carbohydrate (g) Fibre (g) Cost (AUD)*
Average of one Optifast® sachet (54 g) 870 17.5 4.5 22.5 3.6 3.50
Average of one KicStart® sachet (55 g) 856 22.3 3.8 18.4 3.05 2.95
One scoop of Beneprotein® whey protein isolate (7 g) 105 6 0.0 0.0 0.0 0.62
AUD, Australian Dollars.
*Based on price to the consumer of the only available pack sizes: AUD41.95 for a box of 12 Optifast® shakes; AUD2.95 for a single KicStart™
shake; AUD19.95 for a 270 g can of Beneprotein®.
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252–912 kJ, 12.4–34.8 g of carbohydrate and AUD2.89–
5.15 (AUD20.23–36.05 per week).
Once we had selected the VLED product to be used in
our trial based on the previously mentioned consider-
ations (KicStart™), we recalculated our regimens incorpo-
rating vegetable and oil allowances. The vegetable and oil
allowance included two cups of non-starchy vegetables
and one teaspoon of fat or oil. Vegetables are recom-
mended in clinical treatment protocols not only to help
increase fibre intake, as constipation is a common side
effect of VLEDs, but also to help with the social aspects
of eating (28). The teaspoon of oil was originally included
Figure 1 Daily protein intake targets of potential fast weight loss re-
gimes can be met at a lower daily energy intake if KicStart™ very low
energy diet products are used as the basis of the regime rather than
Optifast® products.
Figure 2 Daily protein intake targets of potential fast weight loss re-
gimes can be met at a lower daily carbohydrate intake if KicStart™
very low energy diet products are used as the basis of the regime
rather than Optifast® products.
Table 2 Average daily nutritional composition and cost of two sets of potential fast weight loss regimes modelled using different very low energy
diet products to meet protein requirements of 68–115 g per kg of actual body weight per day
Regime no. No. of shakes No. of
Beneprotein®
scoops (7 g)
Energy (kJ) Protein (g) Fat (g) Carbohydrate (g) Fibre (g) Total cost
(AUD per day)
Total cost
(AUD per week)
OPTIFAST® (54 g)
1 3 2 2820 64.5 13.5 67.5 10.8 11.74 82.18
2 3 3 2925 70.5 13.5 67.5 10.8 12.36 86.52
3 3 4 3030 76.5 13.5 67.5 10.8 12.98 90.86
4 3 5 3135 82.5 13.5 67.5 10.8 13.60 95.20
5 3 6 3240 88.5 13.5 67.5 10.8 14.22 99.54
6 4 4 3900 94.0 18.0 90.0 14.4 16.48 115.36
7 4 5 4005 100.0 18.0 90.0 14.4 17.10 119.70
8 4 6 4110 106.0 18.0 90.0 14.4 17.72 124.04
9 4 7 4215 112.0 18.0 90.0 14.4 18.34 128.38
10 4 8 4320 118 22.5 90.0 14.4 18.96 132.72
KicStart™ (55 g)
1 3 0 2568 67.0 11.5 55.2 9.2 8.85 61.95
2 3 1 2673 73.0 11.5 55.2 9.2 9.47 66.29
3 3 2 2778 79.0 11.5 55.2 9.2 10.09 70.63
4 3 3 2883 85.0 11.5 55.2 9.2 10.71 74.97
5 3 4 2988 91.0 11.5 55.2 9.2 11.33 79.31
6 3 5 3093 97.0 11.5 55.2 9.2 11.95 83.65
7 3 6 3198 103.0 11.5 55.2 9.2 12.57 87.99
8 4 3 3739 107.3 15.3 73.5 12.2 13.66 95.62
9 4 4 3844 113.3 15.3 73.5 12.2 14.28 99.96
10 4 5 3949 119.3 15.3 73.5 12.2 14.90 104.30
AUD, Australian Dollars.
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to cause contraction of the gall bladder and minimize the
risk of gall stones (28). Modern formulations of VLED
products now contain sufficient fat so the addition of oil
to the diet is not essential. However, adding oil to the diet
does allow a greater flexibility and variety of dishes to be
prepared using the vegetable allowance. Vegetables and
oil would not be compulsory for those in the fast weight
loss arm in this trial but would be strongly encouraged
for the aforementioned reasons. For calculation of the
composition of these allowances, we used one third of a
cup each of cauliflower, broccoli, zucchini, spinach, green
beans and carrots plus one teaspoon of olive oil. The nu-
tritional composition of these foods was 400 kJ, 4.2 g
protein, 5.1 g fat, 5.3 g carbohydrate and 6.2 g fibre, which
was analysed with FoodWorks® software version 7 (Xyris
Software (Australia) Pty Ltd., Kenmore Hills, Australia).
The recalculated regimens are shown in Table 3. Note
that only regimens 1–8 are shown: Regimens 9 and 10
were no longer required because the protein content of
the vegetable allowance made them unnecessary.
In order to ensure that our fast weight loss regimens
were indeed meeting our targets of 65–75% energy re-
striction, as well as daily protein and carbohydrate intakes
of 1.0 g per kg and less than 100g, respectively, we
cross-checked our eight regimens against our model of
potential participants (Table 3). As the regimens differed
by 6g increments of protein (the amount of protein in
one 7g scoop of Beneprotein®), and as the regimen a
particular participant would be prescribed would be
based on their starting weight, we used the protein con-
tent of the regimens to determine weight categories.
The upper and lower cut points were taken from the aver-
age protein content of two adjacent regimens. As an ex-
ample, for regimen number 4, protein intake is 89 g per
day, and for regimen number 5, protein intake is 95g
per day (Table 3); therefore, the upper cut point of body
weight for regimen 4 is less than 92 kg, and the lower
cut point of body weight for regimen number 5 is greater
than or equal to 92 kg.
Once the weight categories were determined for each
regimen, we also cross-checked the energy intake of
each regimen against the range of EEEs of potential
participants to be prescribed that regimen, to ensure that
it would involve severe energy restriction for those par-
ticipants. This showed that on average, the energy
Figure 3 Daily protein intake targets of potential fast weight loss re-
gimes can be met at a lower program cost (16 weeks for this trial) if
KicStart™ very low energy diet products are used as the basis of
the regime rather than Optifast® products.
Table 3 Weight categories, nutritional composition and lowest and highest degree of estimated energy restriction of each of the final fast weight
loss regimes using KicStart™ incorporating vegetable and oil allowances
Regime
number
Participant weights
for which this regime
would be used (kg)*
No.of
shakes
No. of
Beneprotein®
scoops (7 g)
Energy
(kJ)
Protein
(g)
Fat
(g)
Carbohydrate
(g)
Fibre
(g)
Lowest ER†
(%)
Highest
ER†(%)
1 68–74 3 0 2.97 71 17 60 15 67 69
2 >74–80 3 1 3.07 77 17 60 15 66 69
3 >80–86 3 2 3.18 83 17 60 15 66 69
4 >86–92 3 3 3.28 89 17 60 15 65 69
5 >92–98 3 4 3.39 95 17 60 15 64 67
6 >98–104 3 5 3.49 101 17 60 15 65 67
7 >104–110 3 6 3.60 107 17 60 15 64 66
8 >110–115 4 3 4.14 112 20 79 18 60 61
ER, energy restriction.
*These weight categories were based on participants’ heights between 1.5 and 1.7m tall. As such, potentially eligible participants may fall out-
side these weight categories, but only if their BMI is on the extremes of our criteria. As such, additional regimes would need to be devised for
those heavier than 115 kg.
†To determine the lowest and highest ER provided by each regimen, we used our model of EEE of potential participants (refer to Supporting
information, Figure S2) to identify the lowest and highest EEE of the potential participants that would be prescribed that regimen (i.e. the lightest
and shortest participants to the heaviest and tallest participants, respectively).
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restriction for each regimen would fall within our required
65–75% energy restriction (Table 3). The exception to this
would be the heaviest potential participants (>110), who
would require four shakes per day (regimen 8) upon
commencement of the intervention, which would result
in an energy restriction of 60–61%, which is lower than
our target range of 65–75%. In summary, our modelling
work has shown that it would be possible to achieve our
aims of providing a weight loss diet involving severe
energy restriction and less than 100g carbohydrate per
day whilst also meeting our protein target of 1 g per kg
of actual body weight per day.
The fast weight loss intervention in the TEMPO Diet
Trial involves 16weeks of severe energy restriction
followed by the same diet as those on the slow weight
loss intervention (details in the succeeding texts), for a to-
tal of 12months. As actual body weight would inevitably
change over the course of the intervention, the regimens
used to achieve fast weight loss would be adjusted every
4weeks. Participants would receive a booklet with infor-
mation about the fast weight loss intervention, including
a list of allowed extras, answers to frequently asked ques-
tions (e.g. side effects and their management) and recipe
suggestions for the non-starchy vegetable allowance.
Development of the slow weight loss intervention
Whilst there are many different ways to achieve slow
weight loss via moderate energy restriction – and the de-
bate about the optimal macronutrient composition of
weight loss diets continues (32) – we chose to base our
slow weight loss intervention on the Australian Guide to
Healthy Eating (AGHE), the Australian Government
Dietary Guidelines released in April 2013 (33). There are
several reasons why the national dietary guidelines of a
country are an ideal basis for a weight loss intervention
in that country (in this case, Australia), notably because
they are based on foods that are typically eaten and easily
accessible in that country by a variety of cultural groups,
as well as being in line with the general goal of weight loss
interventions, as outlined in the succeeding texts.
In addition to targets for energy restriction and protein
intake, the long duration of the slow weight loss interven-
tion (12months) meant that key considerations in design-
ing the regimens to be used for the intervention were
flexibility, acceptability to participants and sustainability.
The AGHE meets these considerations because of the
large amount of choice available within each of the core
food groups and combinations thereof, enabling food
selections to meet taste, cultural and cost preferences
for each participant, including those on vegetarian diets.
Moreover, as the guidelines were developed for use by
the general public, numerous resources on their interpre-
tation and use have been developed, making them an
economical, practical, familiar and convenient tool to
use as the basis of our slow weight loss intervention.
As well as the flexibility and convenience of the AGHE, it
is also nutritionally sound. The AGHE is a dietary guideline
designed to meet nutrient requirements with minimum en-
ergy intake – providing the optimum basis for a weight loss
intervention. After all, the types of foods that are recom-
mended to people for weight loss (high in nutrients, low in
energy) are the same as those that are recommended to
the general population for optimal health and well-being.
The latest Australian National Nutrition Survey showed that
discretionary foods (not part of the five core food groups)
contributed 35–45% of the total energy intake of Australian
adults (34). Discretionary foods are typically energy
dense, low in protein and high in refined carbohydrates
and fat (particularly saturated fat). Further, the latest
Australian Health Survey, which was conducted in 2011–
2012, found that less than 10% of women aged
45–64years consumed the recommended two serves of
fruit and five serves of vegetables every day (35). Taken to-
gether, a decreased consumption of discretionary foods
and increased consumption of fruits and vegetables, as
recommended by the AGHE, aligns with the requirements
of weight loss interventions such as the slow weight loss
intervention to be used in the TEMPO Diet Trial.
The AGHE provides recommendations as to the
average number of standard serves of the five core food
groups an individual should eat in order to meet their
nutritional requirements, based on their age and sex.
Core foods are those that provide nutrients essential for
health, with minimal amounts of added saturated fat,
sugar, salt and alcohol. The five core food groups are
fruits, vegetables, grains and cereals, meat and meat al-
ternatives and reduced fat dairy. A standard serve is an
energy equivalent within a core food group of the AGHE.
For example, all of the standard serves of meat and meat
alternatives in the AGHE (65g of cooked red meat, 120g
of firm tofu, etc.) provides between 500 and 600 kJ. For
the purposes of our slow weight loss intervention, and
to simplify adherence, the meat and meat alternative
Table 4 Average energy and protein provided by a serve of each of
the six food groups used to develop the different regimes for the slow
weight loss intervention
Food group Energy (kJ) Protein (g)
Proteins 550 15
Carbohydrates 500 3
Vegetables 100 2
Fruits 350 1
Fats 350 0
Discretionary 600 2
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and reduced fat dairy core food groups of the AGHE were
collapsed into a ‘proteins’ group, and starchy vegetables
were incorporated into the grains and cereals group to
form a ‘carbohydrates’ group. For females, an allowance
of 14–20g per day of spreads and oils based on unsa-
turated fats is included as part of the AGHE to reflect
culinary behaviour. For the purposes of our intervention,
we defined a ‘fat’ serve as two teaspoons (10 g) of spread
or oil, which provides approximately 350 kJ.
Discretionary choices are defined in the AGHE as foods
that are not essential for health and are therefore not part
of the core food groups. They include foods that are tradi-
tionally referred to as ‘junk foods’, such as biscuits, cakes
and ice cream. However, they also include ingredients
that may be used in food preparation to add flavour to
and increase the palatability of core foods – such as
honey added to porridge or a stir-fry. As such, we consid-
ered it important to include one serve (600 kJ) of discre-
tionary foods per day to not only help with compliance
for the previously mentioned culinary reasons but also
to improve the social aspects of weight loss. For exam-
ple, participants could ‘save up’ their serves of discretion-
ary foods for a social event. In summary, we used the five
core food groups, added fat allowances and discretionary
foods from the AGHE to define six food groups for the
purposes of this intervention: proteins, carbohydrates,
vegetables, fruits, fats and discretionary (Table 4).
To design the regimens for the slow weight loss
intervention, we once again worked backwards from the
desired output, which was a daily protein intake of
68–115g per kg of actual body weight per day (corre-
sponding to the potential weights of our participants of
68–115 kg) and an energy restriction of 25–35% of EEE.
For this purpose, we used the average energy and protein
provided by a serve of each of the six food groups in this
intervention, as shown in Table 4. These values were
determined as described in the succeeding texts.
Although foods are grouped in Table 4 based on the
major types of nutrients they provide, the large number
of foods within each of the food groups means that they
would inevitably vary in energy and protein content. As
such, a number of assumptions were inherent in our
model. For the proteins group, which was formed by
combining the meat and meat alternatives and reduced
fat dairy core food groups of the AGHE, a standard serve
for both in the AGHE is 500–600 kJ. As such, we took the
midpoint of this range and defined the average energy
content of the proteins group as 550 kJ. For the carbohy-
drates group, which was formed by combining the grains
and cereals and starchy vegetables, the energy content of
a standard serve in the AGHE is 500 and 350 kJ, res-
pectively. We increased the energy content of a starchy
vegetable serve to 500 kJ for consistency. For all other
groups, the energy content of a serve was the same as
an AGHE serve (Table 4).
To calculate the average protein content of a standard
serve of the proteins group, as well as that of the other
food groups used for this intervention, we entered a range
of standard serves of different foods from that food group
into a recipe file in FoodWorks® software version 7 (Xyris
Software (Australia) Pty Ltd., Kenmore Hills, Australia) and
then divided the total amount of protein by the number of
serves. For example, for the proteins group, we entered
the following serves into FoodWorks®: 100g of raw lean
beef (22 g of protein, 518 kJ), 100 g of raw lean lamb
(22 g of protein, 546 kJ), 100 g of raw skinless chicken
breast (22 g of protein, 438 kJ), 100 g of raw lean pork
(23 g of protein, 469 kJ), two eggs (13 g of protein,
553 kJ), 100 g of tofu (12 g of protein, 502 kJ), one cup of
reduced fat milk (10 g of protein, 528 kJ), 150 g of reduced
fat fruit yoghurt (8 g of protein, 551 kJ), one half cup
reduced fat ricotta cheese (11 g of protein, 550 kJ) and
40 g of reduced fat cheese (11 g of protein, 561 kJ) and
then divided the total amount of protein in all of these
10 serves (154 g) by the number of serves (10) to get an
average protein content of 15.4 g per standard serve,
which we rounded down to 15g as shown in Table 4.
To develop the slow weight loss regimens, we used a
similar process to that used to develop the fast weight
loss regimens, by increasing the amount of protein (in
increments of half serves of the proteins group), starting
with a minimum of three serves from the proteins group,
until we had regimens that met our target range of protein
intakes (Table 5). We kept the number of serves of foods
from the other groups constant (four serves from the
carbohydrates group, five from the vegetables group,
two from the fruits group, two from the fats group and
one from the discretionary group) – aligning as closely
as possible to the number of standard serves per day
recommended in the AGHE for a 51–70-year-old woman.
In order to ensure that our slow weight loss regimens
were indeed meeting our target of 25–35% energy
restriction and a daily protein intake of 1.0 g per kg, we
cross-checked our seven regimens against our model of
potential participants (Table 5). As the regimens differed
by 7.5 g increments of protein (the amount of protein in
half a serve of foods from the proteins group), and as
the regimen a particular participant would be prescribed
would be based on their starting weight, we used the
protein content of the regimens to determine weight cat-
egories. The upper and lower cut points were taken from
the average protein content of two adjacent regimens. As
an example, for regimen number 3, average protein intake
is 86 g per day, and for regimen number 4, average
protein intake is 94 g per day (Table 5); therefore, the up-
per cut point for regimen 3 is a body weight of less than
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90 kg, and the lower cut point for regimen 4 is a body
weight of greater than or equal to 90 kg.
Once the weight categories were determined for each
regimen, we also cross-checked the energy intake of
each regimen against the range of EEEs of potential
participants to be prescribed that regimen, to ensure that
it would involve moderate energy restriction for those
participants. This showed that on average, the energy
restriction for each regimen would fall within our required
25–35% energy restriction (Table 5). The exception to
this would be the heaviest potential participants (>113–
115 kg), who would start on regimen 7 upon commence-
ment of the intervention, which would result in an energy
restriction of 24. %, which is lower than our target range
of 25–35%. In summary, our modelling work has shown
that it would be possible to achieve our aims of providing
a weight loss diet involving moderate energy restriction
whilst also meeting our protein intake target of 1 g per
kg of actual body weight per day.
Implementation of the fast and slow
weight loss interventions
Implementation of an education-based dietary inter-
vention (as opposed to a dietary intervention where
meals are provided) presents multiple challenges. It
is well known that people consistently eat similar
foods to those they normally eat, even when they
are prescribed special diets. For this reason, all par-
ticipants in the TEMPO Diet Trial would be required
to complete a 7-d food diary prior to beginning the in-
tervention. This would be used not only for data col-
lection of baseline dietary intake but also to
individualize the interventions for each participant.
Participants would be provided with the Australian Di-
etary Guideline resources (available from www.
eatforhealth.com), as well as individualized meal plans
and behavioural resources as appropriate to the interven-
tion to which they are randomized and the stage of the
intervention.
Following randomization, all participants would re-
ceive oral and written information about the dietary
intervention to which they have been randomized.
This information would be provided by an Accredited
Practicing Dietitian (Australian equivalent of a Regis-
tered Dietitian in the UK and USA). The number and
timing of individual dietary appointments used in the
TEMPO Diet Trial was based on the National Health
and Medical Research Council (NHMRC) clinical prac-
tice guidelines for ‘active weight management’ of
adults with a BMI in the overweight and obese range
(36). The recommendations are for appointments every
2weeks for the first 3months and for continued monitor-
ing for 12months. This equates to seven appointments
over the first 3months. We thus decided that participants
in our trial would have seven individual dietary appoint-
ments over 16weeks, as participants would be in contact
with us on other occasions for measurement of trial out-
comes, meaning that despite spreading the seven ap-
pointments over a longer period than that recommended
by the NHMRC, the frequency of contact with our team,
including the Accredited Practicing Dietitian, would actu-
ally be greater.
The initial individual dietary appointment was
scheduled for approximately 90min, with subsequent
review appointments of 30–60min. We would allow
participants the option of doing some of their
Table 5 Average predicted protein and energy intake and the lowest and highest predicted energy restriction of each of the slow weight loss
regimes
Regime
number
Weight of potential
participants for which this
regime would be used (kg)*
No. of protein
serves
No. of carbohydrates/
vegetables/fruits/fats/
discretionary serves Energy (kJ) Protein (g) Lowest ER† (%) Highest ER (%)†
1 >68–75 3 4/5/2/2/1 6.4 71 30 33
2 >75–83 3.5 4/5/2/2/1 6.7 79 33 30
3 >83–90 4 4/5/2/2/1 7.0 86 33 28
4 >90–98 4.5 4/5/2/2/1 7.2 94 33 28
5 >98–106 5 4/5/2/2/1 7.5 101 31 27
6 >106–113 5.5 4/5/2/2/1 7.8 109 30 27
7 >113–115 6 4/5/2/2/1 8.1 116 24 24
ER, energy restriction.
*These weight categories were based on participants’ heights between 1.5 and 1.7 m tall. As such, potentially eligible participants may fall out-
side these weight categories, but only if their BMI is on the extremes of our criteria. In which case, additional regimes would need to be devised
for those heavier than 115 kg.
†To determine the lowest and highest ER provided by each regimen, we used our model of EEE of potential participants (refer to Supporting
information, Figure S2) to identify the lowest and highest EEE of the potential participants that would be prescribed that regimen (i.e. the lightest
and shortest participants to the heaviest and tallest participants, respectively).
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individual dietary appointments over the phone, be-
cause many of the women in our trial would most
likely still be working and may find it difficult to attend
the clinic in person for every appointment and be-
cause the efficacy of dietary interventions delivered
by telephone is supported by evidence (37).
Individual dietary appointments would provide a compre-
hensive weight management consultation that, in addition
to the dietary intervention, addresses key aspects of life-
style modification, namely behaviour change and physical
activity. Although the TEMPO Diet Trial is not an interven-
tion that specifically investigates physical activity, partic-
ipants in both interventions would be given a pedometer
and general advice to gradually increase daily step counts
to 8000–12,000 steps per day, including 30–60min per
day of moderate to vigorous physical activity. This recom-
mendation was based on achieving 200–300min per
week of physical activity, as recommended in the 2009
American College of Sports Physicians guidelines for
weight loss and prevention of weight gain (38).
Conclusion
The purpose of this paper was to present the underly-
ing rationale and development process behind the di-
etary interventions to be used in the TEMPO Diet
Trial. Whilst the TEMPO Diet Trial is more of an effi-
cacy study than an effectiveness study, as it is con-
ducted in a research setting and in a narrowly
defined population, it has been designed to maximize
clinical utility by drawing on existing resources and
clinical practice guidelines. This work has demon-
strated that there are several different steps and con-
siderations that lead to the final intervention – which
is rarely reported in the literature but which could be
useful to readers of outcome papers or to those wish-
ing to design their own dietary weight loss interven-
tions for research or clinical purposes. Reporting
more detailed information about the design and char-
acteristics of dietary interventions could help to
bridge the gap in translating findings from research
into clinical practice.
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